The question whether a direct targeting of c-FLIP and Mcl-1 with chemical compounds is more efficient for the particular anti-cancer treatment compared to downregulation of c-FLIP and Mcl-1 levels has to be addressed in the future studies. The gene discussed is CFLAR; the disease is cancer.